Prognostic Values Of Prevalent Gene Mutations In Intrahepatic Cholangiocarcinoma

Zheng Wang,Xiang-Yu Wang,Jian-Hua Li,Wen-Wei Zhu

2016-01-01

Abstract:Intrahepatic cholangiocarcinoma (ICC) is a complicated and fatal cancer. With the development of sequencing technologies, TP53, KRAS and IDH1/2 have been identified as frequently mutant genes in ICC. However, the prognostic value of these mutations remained uncertain. In order to clarify the prognostic values of these mutant genes in ICC, a systematic search of Pubmed, Embase and Web of Science was performed. Publications which met inclusion and exclusion criteria were finally included. The hazard ratio (HR) and 95% confidence interval (CIs) of TP53, KRAS, and IDH1/2 mutation for overall survival (OS) was extracted from each eligible study. Also, the odds ratio (OR) and 95% CI of these gene mutations for clinical features was extracted. The I-2 and chi(2) tests were applied to assess heterogeneity between the enrolled studies, and P<0.05 indicated statistical significance. If P>0.05, we used a fixed-effects model to calculate the pooled HR to assess the association between gene mutation and overall survival; and if P<0.05, we used a random-effects model. In addition, the pooled OR was calculated to investigate the correlation between gene mutation and clinical features in ICC. A total of 16 studies composing of 1,516 ICC patients were included in the final analysis. Eight articles studied the relationship between TP53 mutation and overall survival, indicating that patients with TP53 mutation had poorer prognosis (HR=2.91, 95% CI: 1.67-5.09). And meta-analysis of eleven studies revealed that KRAS mutation was an adverse prognostic predictor in ICC (HR=2.30, 95% CI: 1.70-3.12). The result of seven studies showed that IDH1/2 mutation had no impact on prognosis of ICC patients (HR=1.02, 95% CI: 0.62-1.67). However, the subgroup analysis suggested that IDH1/2 mutation was a favorable prognostic factor in patients from Asia (HR=0.53, 95% CI: 0.33-0.87), but it could shortened overall survival in patients from America and Europe (HR=1.41, 95% CI: 1.05-1.90). We also found that KRAS mutation was associated with progressive tumor stage (III-IV) (OR=0.31, 95% CI: 0.15-0.63), and that patients with IDH1/2 mutation tended to have poor tumor differentiation (OR=0.41, 95% CI: 0.19-0.90). These findings indicated there are different prognostic roles of TP53, KRAS and IDH1/2 mutations in ICC.